ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

ClinicalTrials.gov ID: NCT03054428

Public ClinicalTrials.gov record NCT03054428. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 10:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Study identification

NCT ID
NCT03054428
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
Regeneron Pharmaceuticals
Industry
Enrollment
251 participants

Conditions and interventions

Eligibility (public fields only)

Age range
12 Years to 17 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 20, 2017
Primary completion
Apr 3, 2018
Completion
Jun 4, 2018
Last update posted
Jul 22, 2019

2017 – 2018

United States locations

U.S. sites
36
U.S. states
23
U.S. cities
34
Facility City State ZIP Site status
Regeneron Investigational Site Birmingham Alabama 35209
Regeneron Investigational Site Gilbert Arizona 85234
Regeneron Investigational Site Bakersfield California 93309
Regeneron Investigational Site Long Beach California 90808
Regeneron Investigational Site Rolling Hills Estates California 90274
Regeneron Investigational Site San Diego California 92123
Regeneron Investigational Site Santa Rosa California 95403
Regeneron Investigational Site Centennial Colorado 80112
Regeneron Investigational Site Denver Colorado 80206
Regeneron Investigational Site Washington D.C. District of Columbia 20016
Regeneron Investigational Site Tampa Florida 33624
Regeneron Investigational Site Macon Georgia 31217
Regeneron Investigational Site Sandy Springs Georgia 30328
Regeneron Investigational Site Chicago Illinois 60611
Regeneron Investigational Site Evansville Indiana 47713
Regeneron Investigational Site Indianapolis Indiana 46256
Regeneron Investigational Site Plainfield Indiana 46168
Regeneron Investigational Site Rockville Maryland 20850
Regeneron Investigational Site Boston Massachusetts 02111
Regeneron Investigational Site Boston Massachusetts 02115
Regeneron Investigational Site Plymouth Minnesota 55441
Regeneron Investigational Site St Louis Missouri 63110
Regeneron Investigational Site Forest Hills New York 11375
Regeneron Investigational Site New York New York 10029
Regeneron Investigational Site Rochester New York 14642
Regeneron Investigational Site Chapel Hill North Carolina 27516
Regeneron Investigational Site Bexley Ohio 43209
Regeneron Investigational Site Tulsa Oklahoma 74136
Regeneron Investigational Site Portland Oregon 97223
Regeneron Investigational Site Portland Oregon 97239
Regeneron Investigational Site Philadelphia Pennsylvania 19104
Regeneron Investigational Site Charleston South Carolina 29407
Regeneron Investigational Site Bellaire Texas 77401
Regeneron Investigational Site San Antonio Texas 78218
Regeneron Investigational Site Norfolk Virginia 23502
Regeneron Investigational Site Seattle Washington 98105

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 9 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03054428, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jul 22, 2019 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03054428 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →